| dc.description.abstract | Purpose: Uric acid has been shown as a predictor and an independent risk factor
for coronary heart disease, but little is known regarding the association of uric
acid levels with coronary blood flow in STEMI. We hypothesized that elevated uric
acid levels would be associated with impaired flow and perfusion in the setting of
STEMI treated with primary PCI.
Methods: 289 patients with STEMI who treated primary PCI were enrolled to
study. Patients were divided into two groups based upon the TIMI flow grade.
No-reflow was defined as TIMI Grade 0, 1 and 2 flows (Group 1). Angiographic
success was defined as TIMI 3 flow (Group 2). Uric acid, MPV and hs-CRP were
measured. MACE were defined as in stent thrombosis, non-fatal myocardial infarction and in-hospital mortality.
Results: There were 126 patients (mean age 63±11 and 71% male) in group 1
and 163 patients (mean age 58±12 and 80% male) in group 2. Uric acid, MPV,
and hs-CRP levels on admission were higher in group 1 (p=0.0001 for each).
A uric acid level ≥5.4 mg/dl measured on admission had a 77% sensitivity and
70% specificity in predicting no reflow at ROC curve analysis. In-hospital MACE
was significantly higher in group 1 (29% vs. 7%, p=0.0001). At multivariate analyses, high plasma uric acid (OR 2.05, 95%CI 1.49–2.81; p<0.0001), hs-CRP
(OR 1.02, 95%CI 1.01–1.03; p=0.0007) and MPV (OR 3.09, 95%CI 1.95–4.89;
p<0.0001) levels were independent predictors of no-reflow post primary PCI and
uric acid (OR 2.75, 95%CI 1.93–3.94; p<0.0001), hs-CRP (OR 1.01, 95%CI 1–
1.02; p=0.006) levels, but not MPV, were independent predictors of in-hospital
MACE. | en_US |
